Ketoconazole is inferior to ritonavir as an alternative booster for saquinavir in a once daily regimen in Thai HIV-1 infected patients

AIDS

Volumn 21, Issue 12, 2007, Pages 1535-1539

  Autar, Reshma Saskia ^a,b   Wit, Ferdinand Wnm ^b   Sankote, Jongkol ^a   Sutthichom, Duanghathai ^a   Kimenai, Elly ^c   Hassink, Elly ^b   Hill, Andrew ^d   Cooper, David A ^e   Phanuphak, Praphan ^a,f   Lange, Joep Ma ^b   Burger, David M ^c   Ruxrungtham, Kiat ^a,f  

^a THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

^f CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

Azoles; Ketoconazole; Protease inhibitors; Ritonavir; Saquinavir; Thailand

Indexed keywords

DIDANOSINE; KETOCONAZOLE; LAMIVUDINE; RITONAVIR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SUBSTITUTION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; THAILAND; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; KETOCONAZOLE; MALE; RITONAVIR; SAQUINAVIR; TREATMENT OUTCOME; VIRAL LOAD;

EID: 34447555623     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3280da8ba8     Document Type: Article

References (19)

1. Arnaiz JA, Mallolas J, Podzamczer D, Gerstoft J, Lundgren JD, Cahn P, et al. Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load. AIDS 2003; 17:831-840.
2. Periard D, Telenti A, Sudre P, Cheseaux JJ, Halfon P, Reymond MJ, et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation 1999; 100:700-705.
3. Kilby JM, Hill A, Buss N. The effect of ritonavir on saquinavir plasma concentration is independent of ritonavir dosage: combined analysis of pharmacokinetic data from 97 subjects. HIV Med 2002; 3:97-104.
4. Cardiello PG, van Heeswijk RP, Hassink EA, Srasuebkul P, Mahanontharit A, Samor TM, et al. Simplifying protease inhibitor therapy with once-daily dosing of saquinavir soft-gelatin capsules/ritonavir (1600/100 mg): HIVNAT 001.3 study. J Acquir Immune Defic Syndr 2002; 29:464-470.
5. Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000; 38:41-57.
6. Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet 2000; 38:111-180.
7. Cardiello PG, Samor T, Burger D, Hoetelmans R, Mahanontharit A, Ruxrungtham K, et al. Pharmacokinetics of lower doses of saquinavir soft-gel caps (800 and 1200 mg twice daily) boosted with itraconazole in HIV-1-positive patients. Antivir Ther 2003; 8:245-249.
8. Collazos J, Martinez E, Mayo J, Blanco MS. Effect of ketoconazole on plasma concentrations of saquinavir. J Antimicrob Chemother 2000; 46:151-152.
9. Grub S, Bryson H, Goggin T, Ludin E, Jorga K. The interaction of saquinavir (soft gelatin capsule) with ketoconazole, erythromycin and rifampicin: comparison of the effect in healthy volunteers and in HIV-infected patients. Eur J Clin Pharmacol 2001; 57:115-121.
10. Khaliq Y, Gallicano K, Venance S, Kravcik S, Cameron DW. Effect of ketoconazole on ritonavir and saquinavir concentrations in plasma and cerebrospinal fluid from patients infected with human immunodeficiency virus. Clin Pharmacol Ther 2000; 68:637-646.
11. Droste JA, Verweij-Van Wissen CP, Burger DM. Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite M8, and nevirapine in human plasma by reversed-phase high-performance liquid chromatography. Ther Drug Monit 2003; 25:393-399.
12. Droste JA, Aarnoutse RE, Koopmans PP, Hekster YA, Burger DM. Evaluation of antiretroviral drug measurements by an interlaboratory quality control program. J Acquir Immune Defic Syndr 2003; 32:287-291.
13. Hauschke D, Kieser M, Diletti E, Burke M. Sample size determination for proving equivalence based on the ratio of two means for normally distributed data. Stat Med 1999; 18:93-105.
14. Sugar AM, Alsip SG, Galgiani JN, Graybill JR, Dismukes WE, Cloud GA, et al. Pharmacology and toxicity of high-dose ketoconazole. Antimicrob Agents Chemother 1987; 31:1874-1878.
15. Autar RS, Ananworanich J, Apateerapong W, Sankote J, Hill A, Hirschel B, et al. Pharmacokinetic study of saquinavir hard gel caps/ritonavir in HIV-1-infected patients: 1600/100 mg once-daily compared with 2000/100 mg once-daily and 1000/100 mg twice-daily. J Antimicrob Chemother 2004; 54:785-790.
16. Huang YC, Colaizzi JL, Bierman RH, Woestenborghs R, Heykants J. Pharmacokinetics and dose proportionality of ketoconazole in normal volunteers. Antimicrob Agents Chemother 1986; 30:206-210.
17. Daneshmend TK. Diseases and drugs but not food decrease ketoconazole 'bioavailability'. Br J Clin Pharmacol 1990; 29:783-784.
18. Como JA, Dismukes WE. Oral azole drugs as systemic anti-fungal therapy. N Engl J Med 1994; 330:263-272.
19. Boffito M, Carriero P, Trentini L, Raiteri R, Bonora S, Sinicco A, et al. Pharmacokinetics of saquinavir co-administered with cimetidine. J Antimicrob Chemother 2002; 50:1081-1084.